Top 3 Leading Manufacturers to Account for Majority of the Revenue Share
The chemotherapy-induced myelosuppression treatment market is dominated by the top 3 major manufacturers, which include Amgen Inc., Teva Pharmaceutical Industries Ltd. and Janssen Pharmaceutical NV. These manufacturers are competing on the basis of the new drug launched, improving geographical product footprints and the prices of products.
The manufacturers in the chemotherapy-induced myelosuppression treatment market are focusing on the expansion of their product portfolios by launching different biosimilars to originator products in various regions.
Amgen Inc. holds a major share of the revenue of the global chemotherapy-induced myelosuppression treatment market. Amgen Inc. is the originator of various biologics and has held patents for various formulations. However, due to the recent patent expiry of various products, it is facing tremendous competition from the new biosimilars that have been introduced in the chemotherapy-induced myelosuppression treatment market by other manufacturers such as Janssen Pharmaceutical NV, Sandoz, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Mylan NV and others.
By undergoing partnerships and collaborations with regional medium as well as large businesses, the manufacturers of chemotherapy-induced myelosuppression treatment market are focusing on expanding their regional product footprint by launching new products as well as their existing portfolio in developed countries.
Early Diagnosis and Reduction in Cancer Mortality Driving Revenue Growth
Cancer is the second leading cause of deaths worldwide. According to the World Health Organization (WHO), the number of deaths due to cancer worldwide in 2015 was 8.8 million. However, according to recent SEER Cancer statistics, the worldwide cancer death rate fell by 26.0% during 1991 - 2015, which can be attributed to early diagnosis that subsequently leads to early treatment.
The global availability of advanced treatment options, such as chemotherapy, radiotherapy & surgical procedures is also boosting the chemotherapy-induced myelosuppression treatment market. The early diagnosis of cancer has enhanced the treatment-seeking rate in the developed world and is slowly improving in developing world, which is, in turn, a major driver of the chemotherapy-induced myelosuppression treatment market.
The chemotherapy-induced myelosuppression treatment holds significant potential for revenue generation in developing countries owing to improving treatment-seeking rates and improving product availability.
Approval of Biosimilars in Chemotherapy-Induced Myelosuppression Formulations
The patent expiry of various originator biologics in the chemotherapy-induced myelosuppression treatment market has created significant opportunity for other manufacturers in the chemotherapy-induced myelosuppression treatment market to launch the biosimilars for these products. Most of the patents in the chemotherapy-induced myelosuppression treatment market were held by Amgen Inc.
However, several of them have expired in the past three to five years, i.e. from 2013 to 2018, which has led to the launch and approval of various biosimilars in the high revenue-generating chemotherapy-induced myelosuppression treatment markets such as North America and Europe. For example, the patent for Amegen Inc.’s Neulasta, a biologic used for the treatment of neutropenia, expired in 2015 in the U.S., following which Sandoz launched Zarxio, the first biosimilar in the U.S.
Although the cost variation between originator formulations and biosimilars is only 15% to 20%, it can reduce the economic burden on patients. The growth of the chemotherapy-induced myelosuppression treatment market can be majorly attributed to the increasing availability of comparatively cost-effective biosimilars in the chemotherapy-induced myelosuppression treatment market.
Extensive Drug Pipeline Likely to Increase the Availability of Cost-Effective Products
Growing emphasis on the research and development of drugs and therapies for chemotherapy-induced myelosuppression treatment in conditions such as neutropenia, anaemia and thrombocytopenia, is expected to create significant growth opportunities in the chemotherapy-induced myelosuppression treatment market. Growing R&D expenditure by pharmaceutical industries for the various drugs used for chemotherapy-induced myelosuppression treatment is expected to boost the product pipeline.
The presence of various clinical-stage pharmaceutical companies, which are focusing on the development of novel drugs for chemotherapy-induced myelosuppression treatment, is expected to be a major forecast impact factor.
Competitive Landscape
This section of the report features the profiles of the key players of the chemotherapy-induced myelosuppression treatment market based on their market shares, differential strategies, product offerings, marketing approach and company dashboard.
Examples of some of the key players featured in this report include Novartis AG, Amgen Inc., Pfizer Inc., Mylan NV, Teva Pharmaceutical Industries Ltd., Myelo Therapeutics GmbH, Janssen Global Services, LLC (Johnson & Johnson), Mission Pharmacal Company, Partner Therapeutics, Inc. and Dova Pharmaceuticals.
The key manufacturers of chemotherapy-induced myelosuppression treatment are focusing on increasing their geographical footprints as well as launching new products to increase their revenue generation in the chemotherapy-induced myelosuppression treatment market.
Definition
Chemotherapy-Induced myelosuppression is defined as the decreased ability of the bone marrow to produce blood cells (WBC, RBC and platelets). It occurs most commonly in cancer patients as an adverse effect of chemotherapy drugs, especially in case of cancers that are located near the bone marrow or near large bones with cavities. Chemotherapy-induced myelosuppression can result in the decreased production of red blood cells (anaemia), white blood cells (leukopenia) and platelets (thrombocytopenia).
About the Report
The company conducted a research study on the chemotherapy-induced myelosuppression treatment market for the forecast period 2018 to 2028. The report offers a comprehensive evaluation of the business opportunities prevailing in the chemotherapy-induced myelosuppression treatment market with insights on the prices, current trends and reimbursement scenario in the chemotherapy-induced myelosuppression treatment market.
Additional Questions Answered
Some of the additional questions addressed in this report on the chemotherapy-induced myelosuppression treatment market:
- What is the overall revenue generation potential of the chemotherapy-induced myelosuppression treatment market across the regions of Europe and Asia-Pacific?
- Who are the key regional and global competitors? What are their portfolios in the chemotherapy-induced myelosuppression treatment market?
- What are the major challenges influencing the growth of the chemotherapy-induced myelosuppression treatment market?
Research Methodology
The chemotherapy-induced myelosuppression treatment market has been estimated based on a supply-demand approach. The market was first calculated based on the epidemiology of myelosuppression in different regions/countries in the chemotherapy-induced myelosuppression treatment. Some of the other qualitative factors analysed include the awareness level and the availability of drugs for chemotherapy-induced myelosuppression treatment for different indications.
This information is further validated with rigorous primary research (which includes interviews, surveys, in-person interactions and the viewpoints of seasoned analysts) and secondary research (which includes verified paid sources, authentic trade journals and resourceful databases).
The research study on the chemotherapy-induced myelosuppression treatment market also includes the top trends and the macro- as well as micro-economic factors shaping the chemotherapy-induced myelosuppression treatment market. With this approach, the report on the chemotherapy-induced myelosuppression treatment market estimates the industry attractiveness of every major segment in the chemotherapy-induced myelosuppression treatment over the forecast period.
Key Segment
Based on indication
- neutropenia
- anaemia
- thrombocytopenia
Based on drug class
- growth factors
- erythropoietin stimulating agents
- thrombopoietic agents
- iron supplements
- others
Based on route of administration
- oral
- injectable
Based on distribution channel
- hospitals pharmacies
- retail pharmacies
- online pharmacies
- drug stores
Based on regions
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific Excluding Japan
- Japan
- Middle East & Africa (MEA)
Need specific information?
In the news
by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights
Our Clients
View Our Reports from Healthcare
View Reports